Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. - Mari,A.; Sallas,W.M.; He,Y.L. (J Clin Endocrinol Metab, 2005)